INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo XYZAL® ORAL SOLUTION

For full prescribing information refer to the package insert approved by the medicines regulatory authority.

SCHEDULING STATUS:
S2

PROPRIETARY NAME
(and dosage form):

XYZAL® ORAL SOLUTION

COMPOSITION:
Each 1 mL oral solution contains 0,5 mg
levocetirizine dihydrochloride.

ATC CLASSIFICATION:
R06A

PHARMACOLOGICAL CLASSIFICATION:
A 5.7.1 Antihistaminics.

PRESENTATION/PACK SIZE:
no data

REGISTRATION NUMBER:
XYZAL ORAL SOLUTION: 41/5.7.1/0032

APPLICANT:
GlaxoSmithKline South Africa (Pty) Ltd
(Co. reg. no. 1948/030135/07),
39 Hawkins Ave, Epping Industria 1, 7460

MANUFACTURER:
UCB PHARMA S.p.A., TURIN, ITALY

AVAILABILITY:
Launched August 2014

ORIGINAL DATE OF REGISTRATION:
27 January 2010

SOURCE:
Launch letter for Oral Solution 2014
ZAF/ALG/0004/14. A18078 07/14.

Date posted:
August 2014

FURTHER READING:
International Links
: (cut and paste the URL)
NOTE the content of these links are for reference only and may not apply to the registration criteria pertaining to The Medicines Control Council in South African.Internet links:

The electronic Medicines Compendium (eMC)
http://www.medicines.org.uk/emc/medicine/19877
PIL: http://www.medicines.org.uk/emc/PIL.19876.latest.pdf

ACTAVIS UK
Levocetirizine dihydrochloride 5 mg film-coated tablets
http://www.medicines.org.uk/emc/medicine/24190

LEVOCETRIZINE - NHS search
http://www.evidence.nhs.uk/medicine/levocetirizine-hydrochloride

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2014